ArticleFrontiers in oncology2023

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer.

Lanqi Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.